Therefore, the antiangiogenic role of microRNA-15a and –16 may contribute, at least in part, to their anti-MM activityTargeting the SDF1-α/CXCR4 pathway with CXCR4 antagonist AMD3100 can mobilize MM cells in the circulation and render them sensitive to anti-myeloma treatment [69]. Here, CXCR4 is linked to Miyoshi myopathy.